Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Minocycline is More Potent Than Tetracycline and Doxycycline in Inhibiting MMP-9 in Vitro

Mina Modheji 1 , Samaneh Olapour 2 , Mohammad Javad Khodayar 2 , Ali Jalili 3 and Hamid Yaghooti 4 , *
Authors Information
1 Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Department of Pharmacology and Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
4 Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: May 01, 2016, 11 (2); e27377
  • Published Online: April 18, 2016
  • Article Type: Research Article
  • Received: March 16, 2015
  • Revised: December 23, 2015
  • Accepted: December 30, 2015
  • DOI: 10.17795/jjnpp-27377

To Cite: Modheji M, Olapour S, Khodayar M J, Jalili A, Yaghooti H. Minocycline is More Potent Than Tetracycline and Doxycycline in Inhibiting MMP-9 in Vitro, Jundishapur J Nat Pharm Prod. 2016 ; 11(2):e27377. doi: 10.17795/jjnpp-27377.

Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A. 1962; 48: 1014-22[PubMed]
  • 2. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2005; 11: 1696-701[DOI]
  • 3. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007; 6(6): 480-98[DOI][PubMed]
  • 4. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92(8): 827-39[DOI][PubMed]
  • 5. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002; 37(6): 375-536[DOI][PubMed]
  • 6. Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J. 2005; 35(6): 331-5[DOI][PubMed]
  • 7. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001; 7(8): 2396-404[PubMed]
  • 8. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006; 11(1): 529-43[DOI]
  • 9. Dorman G, Cseh S, Hajdu I, Barna L, Konya D, Kupai K, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs. 2010; 70(8): 949-64[DOI][PubMed]
  • 10. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010; 299(3)-48[DOI][PubMed]
  • 11. Hu X, Wu B, Wang X, Xu C, He B, Cui B, et al. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011; 654(3): 274-9[DOI][PubMed]
  • 12. Thompson RW, Golub LM. Treatment of aortic and vascular aneurysms with tetracycline compounds. 1998;
  • 13. Wang Y, Morlandt AB, Xu X, Carnes DJ, Chen Z, Steffensen B. Tetracycline at subcytotoxic levels inhibits matrix metalloproteinase-2 and -9 but does not remove the smear layer. J Periodontol. 2005; 76(7): 1129-39[DOI][PubMed]
  • 14. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006; 54(2): 258-65[DOI][PubMed]
  • 15. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006; 7: 56[DOI][PubMed]
  • 16. Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J, et al. Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res. 2008; 1188: 198-206[DOI][PubMed]
  • 17. Toth M, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9 by gelatin zymography. 2001; : 163-74
  • 18. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, et al. Dose–response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006; 26(9): 1157-64[DOI]
  • 19. Yao JS, Shen F, Young WL, Yang GY. Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem Int. 2007; 50(3): 524-30[DOI][PubMed]
  • 20. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem. 2001; 8(3): 305-16[PubMed]
  • 21. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg. 1998; 28(6): 1082-93[DOI]
  • 22. Cazalis J, Tanabe S, Gagnon G, Sorsa T, Grenier D. Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. Inflammation. 2009; 32(2): 130-7[DOI][PubMed]
  • 23. Bannikov GA, Lakritz J, Premanandan C, Mattoon JS, Abrahamsen EJ. Kinetics of inhibition of purified bovine neutrophil matrix metalloproteinase 9 by low-molecular-weight inhibitors. Am J Vet Res. 2009; 70(5): 633-9[DOI][PubMed]
  • 24. Sadowski T, Steinmeyer J. Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm Res. 2001; 50(3): 175-82[PubMed]
  • 25. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone. 1998; 22(1): 33-8[DOI]
  • 26. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL, Copeland J, et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol. 1995; 36(5): 418-24[DOI][PubMed]
  • 27. Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci. 1989; 30(7): 1569-75[PubMed]
  • 28. Garrido-Mesa N, Zarzuelo A, Galvez J. What is behind the non-antibiotic properties of minocycline? Pharmacol Res. 2013; 67(1): 18-30[DOI][PubMed]
  • 29. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza-Hidalgo M, Dillmann W, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol. 2008; 52(13): 1086-94[DOI][PubMed]
  • 30. Bahrami F, Morris DL, Pourgholami MH. Tetracyclines: drugs with huge therapeutic potential. Mini Rev Med Chem. 2012; 12(1): 44-52[PubMed]
  • 31. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res. 2011; 63(2): 102-7[DOI][PubMed]
  • 32. Castro MM, Kandasamy AD, Youssef N, Schulz R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res. 2011; 64(6): 551-60[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments